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A B S T R A C T
Background
Progressive lung damage from recurrent exacerbations is the major cause of mortality and morbidity in cystic fibrosis. Life expectancy of
people with cystic fibrosis has increased dramatically in the last 40 years. One of the major reasons for this increase is the mounting use
of antibiotics to treat chest exacerbations caused by bacterial infections. The optimal duration of intravenous antibiotic therapy is not
clearly defined. Individuals usually receive intravenous antibiotics for 14 days, but treatment may range from 10 to 21 days. A shorter
duration of antibiotic treatment risks inadequate clearance of infection which could lead to further lung damage. Prolonged courses
of intravenous antibiotics are expensive and inconvenient. The risk of systemic side effects such as allergic reactions to antibiotics also
increases with prolonged courses and the use of aminoglycosides requires frequent monitoring to minimise some of their side effects.
However, some organisms which infect people with cystic fibrosis are known to be multi-resistant to antibiotics, and may require a
longer course of treatment. This is an update of previously published reviews.
Objectives
To assess the optimal duration of intravenous antibiotic therapy for treating chest exacerbations in people with cystic fibrosis.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from
comprehensive electronic database searches, handsearches of relevant journals, abstract books and conference proceedings. Most recent
search of the Group’s Cystic Fibrosis Trials Register: 30 May 2019.
We also searched online trials registries. Most recent search of the ClinicalTrials.gov and WHO International Clinical Trials Registry
Platform (ICTRP) portal: 06 January 2019.
Selection criteria
Randomised and quasi-randomised controlled trials comparing different durations of intravenous antibiotic courses for acute respiratory
exacerbations in people with CF, either with the same drugs at the same dosage, the same drugs at a different dosage or frequency or
different antibiotics altogether, including studies with additional therapeutic agents.
Data collection and analysis
No eligible trials were identified for inclusion. A trial looking at the standardised treatment of pulmonary exacerbations is currently
ongoing and will be included when the results are published.
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Main results
No eligible trials were included.
Authors’ conclusions
There are no clear guidelines on the optimum duration of intravenous antibiotic treatment. Duration of treatment is currently based on
unit policies and response to treatment. Shorter duration of treatment should improve quality of life and adherence, result in a reduced
incidence of drug reactions and be less costly. However, the shorter duration may not be sufficient to clear a chest infection and may
result in an early recurrence of an exacerbation. This systematic review identifies the need for a multicentre, randomised controlled trial
comparing different durations of intravenous antibiotic treatment as it has important clinical and financial implications. The currently
ongoing STOP2 trial is expected to provide some guidance on these questions when published.
P L A I N L A N G U A G E S U M M A R Y
Length of time needed for antibiotic treatment given directly into the blood stream to clear acute chest infections in people
with cystic fibrosis
Review question
We reviewed the evidence about how long intravenous antibiotic treatment (antibiotics given directly into the blood stream) is needed
to clear flare ups of chest symptoms in people with cystic fibrosis.
Background
Flare ups of symptoms (exacerbations) in people with cystic fibrosis are treated aggressively to prevent further damage to the lungs.
This practice has led to better survival rates for people with cystic fibrosis in recent years. However, there are no clear guidelines on
how long treatment with intravenous antibiotics should be to treat these flare ups. Different centres tend to use different treatment
regimens. Most centres use 10 or 14 days, extending this to 21 days if there is no improvement in a person’s symptoms. This is an
update of previously published reviews.
Search date
The evidence is current to: 30 May 2019.
Study characteristics
No completed studies have compared different lengths of treatment with intravenous antibiotics, but there is one study under way
looking at this question. When the results are published, we plan to include the study in this review.
Key results
Further research is needed to find the best duration of treatment for exacerbations. A shorter duration of treatment may be better as
these courses of treatment are easier for people to complete. They are also less expensive and cause fewer drug reactions than longer
treatments. However, it is not clear if shorter treatment is enough to treat infections adequately. It is also not clear whether shorter
treatment results in early recurrence or increased frequency of chest infections.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is the most common life-limiting autosomal
recessive genetic disorder in people of northern European descent
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(Farrell 2018), affecting over 10,000 individuals in the UK (Keogh
2018). Respiratory disease is the major cause of mortality and
morbidity in CF (Penketh 1987). About 40 years ago, most people
with CF died in their first decade of life. With advances in treat-
ment, life expectancy has increased dramatically since then with
over half of people born today predicted to live at least 47 years
(Keogh 2018). One of the major reasons for this increase in sur-
vival is the increased use of antibiotics to treat chest exacerbations
caused by bacterial infections.
The abnormal CF gene causes a combination of increased sodium
and defective chloride absorption across the airway epithelium,
which in turn causes dehydration and leads to a build up of thick
sticky mucus. This accumulates in the lungs and causes chronic
pulmonary infections and bronchiectasis. In people with CF, bac-
terial pathogens are the main causes of respiratory exacerbations
(Petersen 1981; Wat 2003).
In small children, Staphylococcus aureus and Haemophilus influen-
zae are the most common organisms isolated and thought to be
responsible for chest exacerbations. In older children and adults,
the major pathogen is Pseudomonas aeruginosa. Burkholderia cepa-
cia and non-tuberculous mycobacteria are also of concern (UK CF
Trust 2018). The most common organism isolated from the spu-
tum of adults is P aeruginosa (Horre 2004), with traditionally
80% of people with CF being infected by 18 years of age (CF
Foundation 2001; Hodson 2000). This is no longer the case and
chronic colonisation with P aeruginosa can be prevented or de-
layed by segregation and aggressive eradication treatment of first
isolates (Hansen 2008; Stuart 2010). Prevalence data from the UK
indicates a rate of chronic P aeruginosa infection of 25.7% in 16
to 19 year olds, rising to a peak of 55.7% in 36 to 39 year olds and
a median in adults of 44.5% (UK CF Trust 2018). Chronic in-
fection with P aeruginosa is however associated with a more rapid
decline in lung function (Emerson 2002; Schaedel 2002).
Most people with CF are initially infected with non-mucoid P
aeruginosa, which is relatively sensitive to antibiotics, but after a
period of time it changes to a mucoid state (Starner 2005). Early
acquisition of mucoid P aeruginosa was associated with a four-fold
greater decrease in cumulative survival (Demko 1995). Mucoid P
aeruginosa is much more difficult to treat and eradicate because it
adopts a defensive mode of growth that leads to creation of a sur-
rounding biofilm (Hentzer 2001; Høiby 2000). Biofilms are com-
munities of bacteria enclosed in a self-produced polysaccharide
matrix and which are adherent to a surface. The biofilm protects P
aeruginosa from normal host defences and antibiotics. In addition,
bacterial adherence to mucus is increased in CF which also con-
tributes to difficulties in clearing it from the airways (Donaldson
2003).
Description of the intervention
At the time of initial infection, the majority of P aeruginosa iso-
lates are susceptible to commonly used antibiotics but, as indi-
viduals are exposed to repeated courses of antimicrobial therapies,
they often develop drug resistance (Gilligan 1999). Multi-resis-
tant P. aeruginosa is associated with more severe lung disease, more
rapid decline in forced expiratory volume in one second (FEV1)
and progression to end-stage lung disease (Lechtzin 2006). People
with CF who are infected with multi-resistant P aeruginosa require
longer duration of intravenous antibiotics, more courses of intra-
venous antibiotics per year and more clinic visits (Lechtzin 2006).
Certain highly transmissible P aeruginosa strains, which can be
detected by genomic fingerprinting, are also known to be multi-
resistant and have a greater requirement for intravenous antibiotics
than those harbouring unique strains (Jones 2002). These epi-
demic, multi-resistant strains can spread among people with CF
with significant resource implications (Cheng 1996; Edenborough
2004; Jones 2001). Other organisms which infect people with CF
and are known to be multi-resistant to antibiotics are B cepacia
complex, Stenotrophomonas maltophilia and Achromobacter (Alka-
ligines) xyloxidans (Elborn 2004). Infection with multi-resistant
organisms is associated with more severe respiratory exacerbations
requiring a longer duration of intravenous antibiotics (Frangolias
1999; Lechtzin 2006).
Intravenous antibiotics are given either as home intravenous an-
tibiotic treatment (HIVAT) or in hospital. For the treatment of
chest exacerbations, the choice of intravenous antibiotics is in-
fluenced by recent culture results of airway secretions, individual
tolerance and previous clinical results. In infections caused by P
aeruginosa, a combination of an aminoglycoside and a beta lac-
tam is preferred as it enhances the activity against target organisms
(synergy) and decreases the risk of antibiotic resistance developing
(Cheng 1996).
How the intervention might work
Deciding on an optimal combination of antibiotic regimens de-
pends on many factors, namely the type of organisms, antibi-
otic sensitivity, allergies, previous response to treatment and local
policies. Yet the cause of treatment failure is complex and varied
(Parkins 2012). A good response to treatment can be expected if
a suitable antibiotic combination is chosen.
The duration of a course of intravenous therapy to treat chest exac-
erbations varies but these are frequently between 10 and 21 days of
antibiotics (CF Trust 2009; Doring 2000; Döring 2012; Gibson
2003; Hodson 2000). The optimal duration of intravenous an-
tibiotic therapy is not clearly defined (Flume 2009). There is a
school of thought that there is limited evidence for fixed durations
of treatment and instead to treat until symptoms are improved
and the individual is close to baseline (Stephen 2018). Response
to therapy (as reflected by improved pulmonary function, oxy-
gen saturation returning to pre-exacerbation levels, levelling off
of weight loss, normalisation or significant falls in inflammatory
markers, decreased bacterial density in sputum, improved well-
being and clinical symptomatology scores) may be used to guide
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the optimal duration of intravenous antibiotic therapy (CF Trust
2009; Döring 2012; Ramsey 1996).
Individuals are usually commenced on a 10- to 14-day course
of intravenous antibiotics (CF Trust 2009; Doring 2000; Döring
2012). This may be extended in people with severe exacerbations
and incomplete recovery (Doring 2000; Döring 2012). Some stud-
ies also mention 10 days (CF Trust 2009; Doring 2000; Hodson
2000) and 21 days (Gibson 2003; Ramsey 1996) as the dura-
tion required to treat chest exacerbations. With a shorter dura-
tion of antibiotic treatment there is a risk of inadequate clearance
of infection which could lead to further lung damage. Prolonged
courses of intravenous antibiotics are expensive and inconvenient
to individuals. The incidence of allergic reactions to antibiotics
also increases with prolonged courses (Koch 1991; Parmar 2005).
Moreover, the use of aminoglycosides requires frequent monitor-
ing of antibiotic levels to avoid some of their side effects namely,
ototoxicity and nephrotoxicity (Hodson 2000).
Why it is important to do this review
The aim of this review is to assess the available evidence in order
to establish the optimal duration of intravenous antibiotic therapy
for treating a chest exacerbation in people with CF. This is an
update of previously published reviews (Plummer 2011; Plummer
2013; Plummer 2016).
O B J E C T I V E S
To assess the optimal duration of intravenous antibiotic therapy
for treating chest exacerbations in people with cystic fibrosis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and quasi-RCTs.
Types of participants
People with CF, diagnosed clinically and by sweat or genetic test-
ing, of all ages and all degrees of disease severity and who are being
treated with intravenous antibiotics for a chest exacerbation.
We will require all studies to clearly state how they will define a
chest exacerbation. We will regard as important or as a minimum,
according to criteria published by the 1994 Cystic Fibrosis Foun-
dation Microbiology and Infectious Disease Consensus Confer-
ence (CF Foundation 1994), the presence of at least three of the
following 11 new findings or changes in clinical status when com-
pared to the most recent baseline visit:
1. increased cough;
2. increased sputum production, change in appearance of
expectorated sputum, or both;
3. fever (greater or equal to 38°C for at least four hours in a
24-hour period) on more than one occasion in the previous week;
4. weight loss greater than or equal to 1 kg or 5% of
bodyweight associated with anorexia and decreased dietary
intake;
5. school or work absenteeism (due to illness) in the previous
week;
6. increased respiratory rate, increased work of breathing, or
both;
7. new finding on chest examination (e.g. rales, wheezing,
crackles);
8. decreased exercise tolerance;
9. decrease in FEV1 of greater than or equal to 10% from
previous baseline study within past three months;
10. decrease in oxygen saturation (as measured by oximetry)
from baseline value within past three months of greater than or
equal to 10%;
11. new finding on chest radiograph.
For paediatric chest exacerbations, the presence of three or more
of the following characteristics will be used to define a chest exac-
erbation:
1. in children under six years of age - new crackles, increased
cough frequency, decline in weight and impression of increased
sputum production;
2. in children six years or over - relative decrease in per cent
predicted FEV1, increased cough frequency, new crackles and
haemoptysis (Rabin 2004).
For the purpose of this study we will exclude people with CF who
are treated electively with intravenous antibiotics and eradication
regimens and only consider people with CF being treated for acute
chest exacerbations.
Types of interventions
Comparison of different durations of intravenous antibiotic
courses, which can either be the same drugs at the same dosage,
the same drugs at a different dosage or frequency or different an-
tibiotics altogether. We will not exclude studies in which there are
additional therapeutic agents included e.g. prednisolone, azithro-
mycin, dornase alpha or nebulised tobramycin or colistin.
Types of outcome measures
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Short-term outcomes
Primary outcomes
1. Lung function (absolute change or percentage change
compared to baseline values or both)
i) forced expiratory volume at one second (FEV1)
(measured in L/min or % predicted)
ii) forced vital capacity (FVC) (measured in L/min or %
predicted)
iii) expiratory flow from 25% to 75% of vital capacity
(FEF25−75)
2. Change in sputum bacteriology (quantitative e.g. colony-
forming units per ml, or qualitative e.g. type of bacteria, or both)
3. Adverse effects (e.g. allergic reactions, candidal infections)
Secondary outcomes
1. Quality of life (measured by health status questionnaires, if
available)
2. Change in nutritional status (absolute change or percentage
change or both compared with baseline values) - Post hoc change:
ideally, the following measures should be age-adjusted in
paediatric participants
i) weight
ii) height
iii) body mass index (BMI)
3. Time to next exacerbation
4. Change in inflammatory markers
i) measured in the sputum
ii) measured in the blood
5. Cost
6. Treatment failure (defined as need to change to a different
course of antibiotics because of clinical deterioration of the
participant)
Long-term outcomes
Primary outcomes
1. Frequency of exacerbations of chest disease
2. Lung function (absolute change or percentage change
compared to baseline values or both)
i) FEV1 (measured in L/min or % predicted)
ii) FVC (measured in L/min or % predicted)
iii) FEF25−75
3. Development of antibiotic-resistant strains
i) Pseudomonas aeruginosa
ii) other organisms
Secondary outcomes
1. Adverse effects (e.g. decline in renal function)
2. Number of intravenous antibiotic courses since study
3. Quality of life (measured by health status questionnaires, if
available)
4. Cost
Search methods for identification of studies
There were no restrictions due to language or publication status.
Electronic searches
We identified relevant trials from the Group’s Cystic Fibrosis Trials
Register using the terms: antibiotics AND (intravenous OR not
stated).
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(Clinical Trials) (updated each new issue of The Cochrane Library),
quarterly searches of MEDLINE, a search of EMBASE to 1995
and the prospective handsearching of two journals - Pediatric Pul-
monology and the Journal of Cystic Fibrosis. Unpublished work is
identified by searching the abstract books of three major cystic
fibrosis conferences: the International Cystic Fibrosis Conference;
the European Cystic Fibrosis Conference and the North American
Cystic Fibrosis Conference. For full details of all searching activi-
ties for the register, please see the relevant sections of the website.
Date of most recent search of the Cystic Fibrosis Trials Register:
30 May 2019.
We also searched the online trials databases as detailed in the ap-
pendices (Appendix 1). Date of latest search: 06 January 2019.
Data collection and analysis
We were unable to identify any trials eligible for inclusion in this
review. If we identify relevant trials for a future update we plan to
undertake the following.
Selection of studies
Two authors (AP, LA or ZHH) will independently apply the in-
clusion criteria to all potential trials. We will perform this without
blinding. Any discrepancy that occurs in the trial selection will be
resolved by discussion.
Data extraction and management
Two authors (AP, LA or ZHH) will independently extract the data
(using a customised data extraction form) and assess the method-
ological quality of the selected trials. Any discrepancy that occurs
in the trial selection will be resolved by discussion.
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For short-term outcomes, we plan to measure outcomes at less
than a week, one to two weeks, more than two weeks to three
weeks, more than three weeks to four weeks. We will also consider
additional follow-up data recorded at other time periods.
Long-term outcomes will be measured from six months following
the end of the course of antibiotics in the study. For long-term
outcomes, we plan to measure outcomes at one month, up to three
months, up to six months, up to twelve months and then annually
thereafter. If outcome data are recorded at other time periods we
will consider examining these as well.
Assessment of risk of bias in included studies
The risk of bias will be assessed using The Cochrane Collabora-
tion “risk of bias” tool (Higgins 2011), The risk of bias will be
considered for the following sections.
1. Sequence generation: a detailed description of the method
of used to generate the sequence allocation will be obtained and
evaluated for the ability to produce bias.
2. Allocation concealment: a detailed description of the
methods used will be obtained. The ability to predict the
randomisation of the current or future patients will be assessed.
3. Blinding: as any eligible studies will be randomised
controlled trials of duration of intravenous antibiotics the
patients and clinicians will be aware of the duration of treatment
unless placebo medicines are given for the additional days. Given
the nature of the drugs and the effects it is likely that these could
be detected by patients and healthcare professionals. The ability
of any methods used to reduce bias will be considered in the
following groups, patient, clinician and outcome assessor.
4. Incomplete outcome data: we will review incomplete data
for each main outcome for both attrition and exclusions. The
studies will be assessed for an intention-to-treat analysis.
5. Selective reporting: the outcomes will be reviewed for
completeness of presentation. Any suggestions of selective
reporting will be followed up with the authors.
6. Other potential sources of bias: any other potential sources
of bias will be considered according to the questions the study is
answering.
Measures of treatment effect
For binary outcome measures (adverse effects, treatment failure),
in order to allow an intention-to-treat analysis, we will seek data on
the number of participants with each outcome event, by allocated
treated group, irrespective of compliance and whether or not the
individual was later thought to be ineligible or otherwise excluded
from treatment or follow up. We aim to calculate a pooled esti-
mate of the treatment effect for each outcome across studies using
relative risk where appropriate.
For continuous outcomes (lung function, change in sputum bac-
teriology, quality of life, change in nutritional status, change in
inflammatory markers), we plan to record either mean relative
change from baseline for each group or mean post-treatment or
intervention values and standard deviation (SD). If standard errors
(SEs) are reported, and where possible, these will be converted to
SDs. We will calculate a pooled estimate of treatment effect by
calculating the mean difference (MD) with corresponding 95%
confidence intervals (CIs).
For any time-to-event outcome included in the review (time to
next exacerbation), we plan to obtain a mixture of logrank and Cox
model estimates from the trials; we will combine all results using
the generic inverse variance method since we will be able to convert
the logrank estimates into log hazard ratios and SEs as detailed
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
We will analyse longitudinal data using the most appropriate
method available.
Unit of analysis issues
Ideally, when conducting a meta-analysis combining results from
cross-over trials we will use the inverse variance methods that are
recommended by Elbourne (Elbourne 2002). However, if there
are restrictions on the data available, we may only be able to either
use the first-arm data only or to treat the cross-over trials as if they
are parallel trials. Elbourne says that this approach will produce
conservative results as it does not take into account within-patient
correlation (Elbourne 2002). Also each participant will appear in
both the treatment and control group, so the two groups will not
be independent.
Dealing with missing data
We will contact the authors of the original studies for data for
any missing individuals, outcomes or summary data. We plan to
describe the implications of any missing data in detail and include
this in the discussion. We may impute missing standard deviations
according to the methodology described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We will
collect any outcomes not available and report these in a risk of
bias table. We plan to conduct an intention-to-treat analysis by
contacting all authors for missing data. If there are large amounts
of missing data which we can not impute with more than minimal
assumptions, we will perform an available case analysis.
Assessment of heterogeneity
We plan to quantify the impact of statistical and clinical hetero-
geneity in the meta-analysis using a measure of the degree of in-
consistency in the studies’ results (Higgins 2003). This measure
(I²) describes the percentage of total variation across studies that
are due to heterogeneity above that due to chance. The values of
I² lie between 0% and 100%, and a simplified categorisation of
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heterogeneity that we plan to use is of listed below (Higgins 2011)
:
• 0 to 40% might not be important;
• 30 to 60% may represent moderate heterogeneity;
• 50 to 90% may represent substantial heterogeneity;
• 75 to 100% represents considerable heterogeneity.
Assessment of reporting biases
We will attempt to assess whether our review is subject to publi-
cation bias by using a funnel plot. If we detect asymmetry, we will
explore causes other than publication bias.
Data synthesis
If we do not identify substantial heterogeneity (as defined above),
we will compute pooled estimates of the treatment effect for each
outcome under a fixed-effect model.
Subgroup analysis and investigation of heterogeneity
If we find substantial heterogeneity, we will investigate the possible
causes of this further by exploring the impact of methodological
quality and condition of the individuals (i.e. severity of disease,
type of treatment, e.g. single or combined treatment) using sub-
group analysis.
We will perform a subgroup analysis based on bacteriology - chron-
ically infected with P aeruginosa only, P aeruginosa and other or-
ganisms (excluding B cepacia), B cepacia (with or without co-infec-
tion with other organisms) and non-P aeruginosa organisms (ex-
cluding B cepacia). Chronic infection is defined as at least two pos-
itive sputum cultures in the previous six months (CF Trust 2009).
We will compare duration of treatment used in HIVAT and hospi-
tal treatment separately. However, comparison of home versus HI-
VAT is the subject of another Cochrane Review (Balaguer 2008)
and this comparison is included here only as part of subgroup
analysis to assess its impact on duration of treatment.
We will also compare duration of treatment based on age separately
in three groups: under six years of age; between six and sixteen
years of age; and over 16 years of age.
Sensitivity analysis
We plan to perform a sensitivity analysis based on the method-
ological quality of the trials, including and excluding quasi-ran-
domised trials.
Summary of findings tables
In a post hoc change, we plan to present a summary of findings
table for each comparison we report in the review. In each table
we will present the results of the following outcomes:
1. absolute change in % predicted FEV1 pre and post IV
antibiotic course;
2. absolute change in % predicted FVC pre and post
antibiotic course;
3. time to next exacerbation;
4. adverse events.
We will determine the quality of the evidence using the GRADE
approach; and will downgrade evidence in the presence of a high
risk of bias in at least one study, indirectness of the evidence, un-
explained heterogeneity or inconsistency, imprecision of results or
high probability of publication bias. We will downgrade evidence
by one level for a serious limitation and by two levels if very seri-
ous.
R E S U L T S
Description of studies
Results of the search
A total of 297 papers were obtained from the Group’s Cystic Fi-
brosis Trials Register and a further 54 records from online trials
registries - as detailed in the PRISMA diagram (Figure 1). Out
of the papers identified from the Group’s Cystic Fibrosis Trials
Register, only 84 papers involved treatment of chest exacerbations
with intravenous antibiotics. The rest of the trials were excluded
immediately because they involved oral or nebulised antibiotics
or were pharmacokinetic trials, trials concerning method of deliv-
ery or without any clinical outcome measures. None of the RCTs
identified compared different durations of antibiotic courses and
are therefore not eligible for inclusion in this review. We have ex-
cluded 14 trials (23 references) and the reasons for exclusion are
provided in the tables (Characteristics of excluded studies). We
have identified one ongoing trial (six references) (STOP2).
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Figure 1. Study flow diagram.
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Included studies
No trials were identified which were eligible for inclusion in this
review.
Excluded studies
A total of 14 trials were excluded. One trial was abandoned due to
low recruitment (NCT01044719), another was excluded due to
its observational trial design (STOP 2017) and the remaining 12
trials did not compare duration of treatment with IV antibiotics
(Adeboyeku 2011; Blumer 2005; Hjelte 1988; Hubert 2009;
Kapranov 1995; Keel 2011; Kenny 2009; Knight 1979; Latzin
2008; Postnikov 2007; Riethmueller 2009; Semykin 2010).
Ongoing studies
One trial is listed as ongoing and expected to report results in
2020 (STOP2). This RCT has a parallel design with three separate
arms. It is a multicentre trial being run at 58 centres in the USA
and Canada (only one of the centres is in Canada). Participants
are adults (18 years and over) and of either gender, who are being
treated with IV antibiotics for a pulmonary exacerbation; they can
only participate once in this trial. Courses of antibiotics of different
durations are being compared (10 days versus 14 days versus 21
days) and may be administered either in hospital or at home. The
treating physician will decide on the choice of antibiotics. The
primary outcome is the change from baseline in FEV1 % predicted
at 14 days after the course of antibiotics has been completed.
Secondary outcomes are a change in symptom score and a change
in weight at the same time point (STOP2).
Risk of bias in included studies
No trials were identified which are currently eligible for inclusion
in this review.
Effects of interventions
No trials were identified which are currently eligible for inclusion
in this review.
D I S C U S S I O N
CF is a life-limiting disease. While every effort needs to be fo-
cused on treating chest infections aggressively, there is still no clear
guidance on how long the optimum duration of IV antibiotics
should be. We did not find any RCTs comparing different treat-
ment durations. Reducing the treatment duration to 10 days may
have significant benefits; improved quality of life, improved com-
pliance, less incidence of drug reactions and lower cost. However,
it is uncertain if this duration of 10 days is sufficient to clear a chest
infection and does not result in an early recurrence of next exac-
erbation. Moreover, multi-resistant organisms may require longer
duration to treat them effectively.
One prospective observational study identified the mean duration
of IV antibiotics as 15.9 days but this varied according to an in-
dividual’s characteristics (STOP 2017). A USA registry analysis
determined that treatment courses less than nine days are associ-
ated with early treatment failure and 10 days is considered to be
the minimum duration (VanDevanter 2016). A further study has
suggested that there may be benefit with extending IV duration
beyond 14 days for some people (Waters 2015). None of these
studies are RCTs which compare different durations of antibiotic
courses and are therefore not eligible to be included in the Results
section of this Cochrane Review. There are no clear reasons for
choosing 14 days or 21 days as the optimum duration, besides the
assumption that longer treatment may clear the infection more
thoroughly.
In most adults and adolescents with CF, eradication of the infect-
ing bacterial organism is almost impossible as infections tend to
be chronic and ineradicable. Therefore, extending the duration of
antibiotic therapy would not be expected to result in the clearance
of infection. In contrast to acute infections associated with other
diseases, the duration of antibiotic therapy for CF exacerbations
should probably be guided based on improvement in clinical sta-
tus of the affected individual rather than based on attempts at ren-
dering the airways sterile of bacteria.
Moreover, not all chest exacerbations are due to the usual bacteria
known to infect the lungs of people with CF. Viruses, atypical
bacteria and fungi are also implicated in causing exacerbations
(Olesen 2006). UK prevalence data indicates a rate of infection
with Mycobacterium abcessus of 3.8% (UK CF Trust 2018) and
significantly longer durations of IV antibiotics may be required to
treat this organism. Current recommendations in the UK advise
a minimum of one month of IV antibiotics for initial treatment,
with the duration determined by severity of infection, response to
treatment and tolerability of the regimen (BTS 2017).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There are no published data to recommend the optimum duration
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of intravenous antibiotic therapy for treating a chest exacerbation
in people with cystic fibrosis. Duration of treatment is currently
decided based on unit policies and the individual’s response to
treatment and we have found no evidence to change this practice.
The role of nebulised antibiotics to replace IV antibiotics may have
implications for practice but is outside the remit of this review.
Implications for research
This Cochrane Review has identified the need for a well-designed,
adequately-powered, multicentre randomised controlled trial to
assess the optimum duration of intravenous antibiotic therapy to
treat chest exacerbations in people with cystic fibrosis, an issue
which has important clinical and financial implications. This ques-
tion is expected to be addressed by the identified ongoing trial
which is due for completion in 2020 (STOP2).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adeboyeku 2011 Not duration of treatment, comparison of 2x versus 3x daily antibiotics for pulmonary exacerbations
Blumer 2005 Not duration of treatment, compared different courses of antibiotics
Hjelte 1988 Not duration of treatment, effect of home intravenous antibiotics on quality of life
Hubert 2009 Pharmacokinetic study.
Kapranov 1995 Not intravenous antibiotics or duration of treatment.
Keel 2011 Comparison of oral versus intravenous 2x daily linezolid for 9 doses in each group
Kenny 2009 Eradication therapy - an exclusion criteria.
Knight 1979 Not intravenous antibiotics or duration of treatment.
Latzin 2008 Length of therapy varies and not specified.
NCT01044719 Abandoned due to low recruitment.
Postnikov 2007 2x versus 1x dosing, not duration of treatment.
Riethmueller 2009 Not duration of treatment, study of elective 3x daily antibiotics for chronic Pseudomonas aeruginosa.
Semykin 2010 Not duration of treatment, comparison of different courses of antibiotics for pulmonary exacerbations where
all participants received 14 days of antibiotics
STOP 2017 Observational study.
Characteristics of ongoing studies [ordered by study ID]
STOP2
Trial name or title Standardized Treatment of Pulmonary Exacerbations II (STOP2)
Methods RCT.
Design: parallel with 3-arms.
Location: USA and Canada.
Multicentre: 58 centres.
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STOP2 (Continued)
Participants Target recruitment is 1300 participants.
Inclusion criteria
• Male or female ≥18 years of age at Visit 1
• Documentation of a CF diagnosis
• Enrolled in the CF Foundation National Patient Registry prior to Visit 1 (USA sites only)
• At the time of Visit 1, there is a plan to initiate IV antibiotics for a pulmonary exacerbation
• Performed spirometry at Visit 1 and Visit 2 and willing to perform spirometry at Visit 3
• Completed the CRISS questionnaire at Visit 1 and Visit 2 and willing to complete the Cystic Fibrosis
Respiratory Symptoms Diary (CFRSD) questionnaire at Visit 3
• Willing to adhere to a specific treatment duration determined by initial response to treatment and
subsequent randomization
• Willing to return for follow up Visit 3
• Written informed consent obtained from the participant or their legal representative
Exclusion criteria
• Previous randomization in this study
• Treatment with IV antibiotics in the 6 weeks prior to Visit 1
• Admission to the intensive care unit for current pulmonary exacerbation in the 2 weeks prior to Visit
2, unless admission was due to a desensitization protocol
• Pneumothorax in the 2 weeks prior to Visit 2
• Primary diagnosis for current hospitalization is unrelated to worsening lower respiratory symptoms (e.
g., pulmonary clean out, DIOS, sinusitis)
• Massive haemoptysis defined as > 250 cc in a 24 hour period or 100 cc/day over 4 consecutive days
occurring in the 2 weeks prior to Visit 2
• Current pulmonary exacerbation thought to be due to ABPA
• At Visit 1, receiving ongoing treatment with a duration of more than 2 weeks with prednisone
equivalent to >10 mg/day
• History of solid organ transplantation
• Receiving antimicrobial therapy to treat non-tuberculous mycobacterium (e.g., M abscessus, M avium
complex) in the 2 weeks prior to Visit 2
Interventions Arm 1: IV antibiotics (to be selected by treating physician) for 10 days
Arm 2: IV antibiotics (to be selected by treating physician) for 14 days
Arm 3: IV antibiotics (to be selected by treating physician) for 21 days
Note: differing durations of IV treatment to be given in the hospital or at home for a pulmonary exacerbation
Outcomes Primary outcome: absolute FEV1 % predicted - change from baseline to 14 days post IV completion
Secondary outcomes: change in CRISS score from baseline to 14 days post IV completion; change in weight
from baseline to 14 days post IV completion
Starting date June 2016 (estimated completion date - February 2020)
Contact information Principle investigators: Chris Goss and Patrick Flume.
Chris Goss, MD
University of Washington Medical Center, 1959 N.E. Pacific, Campus Box 356522, Seattle, WA 98195-
6522, USA
Telephone: +1 206 616 1058
Email: goss@u.washington.edu
Patrick Flume, MD
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STOP2 (Continued)
Department of Medicine, Division of Pulmonary and Critical Care, Medical University of South Carolina,
96 Jonathan Lucas Street, 812-CSB, Charleston South Carolina 29403, USA
Telephone: +1 843 792 9219
Email: flumepa@musc.edu
Notes Clinical trial identifier: NCT02781610
Collaborators: Cystic Fibrosis Foundation; CF Therapeutics Development Network Coordinating Center;
Medical University of South Carolina; University of Washington
ABPA: allergic bronchopulmonary aspergillosis
CF: cystic fibrosis
CFRSD: cystic fibrosis respiratory symptoms diary
CRISS: chronic respiratory infection symptom score
DIOS: distal intestinal obstruction syndrome
FEV1: forced expiratory volume in 1 second
IV: intravenous
A P P E N D I C E S
Appendix 1. Search strategies for online databases
Database Search terms Date last searched
ClinicalTrials.gov
(clinicaltrials.gov/)
Status: all studies
Condition/Disease: cystic fibrosis
Other terms: intravenous antibiotic
06 January 2019
WHO ICTRP portal
(apps.who.int/trialsearch/)
Search term: cystic AND fibrosis AND in-
travenous AND antibiotic
Phases: all
06 January 2019
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W H A T ’ S N E W
Date Event Description
22 August 2019 New search has been performed A search of the Cochrane Cystic Fibrosis and Genetic
Disorders Review Group and additional searches identi-
fied nine new references potentially eligible for inclusion
in the review
One new reference to an already excluded trial was iden-
tified (Hubert 2009).
We identified two new trials: one (with two refer-
ences) was excluded (abandoned due to low recruitment)
(NCT01044719); and one trial (with six references) is
listed as ongoing with results expected in 2020 (STOP2)
.
22 August 2019 New citation required but conclusions have not changed Two new authors have joined the review team (Linsey
Abbott and Zhe Hui Hoo) and one author has stepped
down (Tim Gleeson)
The some text sections of the review have been up-
dated to ensure continued relevance and to reflect cur-
rent opinion and practice
H I S T O R Y
Protocol first published: Issue 3, 2007
Review first published: Issue 2, 2008
Date Event Description
20 July 2016 New search has been performed A search of the Cochrane Cystic Fibrosis and Genetic
Disorders Review Group did not identify any new stud-
ies potentially eligible for inclusion in the review. Five
additional references to two already excluded studies
were identified (Hubert 2009; Riethmueller 2009).
20 July 2016 New citation required but conclusions have not
changed
A new author, Tim Gleeson, has joined the review team
at this review update and is now lead author
No new data have been added to the review, therefore
our conclusions remain the same
27 March 2013 New search has been performed A search of the Cystic Fibrosis & Genetic Disorders
Review Group’s Cystic Fibrosis Register identified five
new references to four studies potentially eligible for
inclusion in this review; all were excluded (Adeboyeku
2011; Keel 2011; Riethmueller 2009; Semykin 2010).
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(Continued)
27 March 2013 New citation required but conclusions have not
changed
No new studies were included in this update of the
review, therefore our conclusions have not changed
3 December 2010 New citation required but conclusions have not
changed
The lead author (Martin Wildman) has stepped down
from this role, but remains a co-author on this review.
The lead author is now Amanda Plummer. One author
(Bryan Fernandes) has left the author team
3 December 2010 New search has been performed A search of the Group’s Cystic Fibrosis Register identi-
fied six new references. The references were all excluded
from this review, as was the one outstanding reference
awaiting classification from the original review (Hjelte
1988).
1 April 2008 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
did not identify any references eligible for inclusion in
this review
31 March 2008 Amended Converted to new review format.
Post hoc change: see Long-term outcomes
two primary outcome measures have been more appro-
priately re-classified as secondary outcome measures
C O N T R I B U T I O N S O F A U T H O R S
Original protocol and review
Task Author
Conceiving the review MW, BF
Designing the review MW, BF, AP
Coordinating the review MW, AP
Data collection for the review BF, AP
Developing search strategy MW, BF, AP
Undertaking searches BF, AP
Screening search results BF, AP
Organising retrieval of papers BF, AP
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(Continued)
Screening retrieved papers against inclusion criteria BF, AP
Appraising quality of papers BF, AP
Abstracting data from papers BF, AP
Writing to authors of papers for additional information BF, AP
Providing additional data about papers MW, BF, AP
Obtaining and screening data on unpublished studies BF, AP
Data management for the review BF, AP
Entering data into RevMan BF, AP
Analysis of data BF, AP
Interpretation of data MW, BF, AP
Providing a methodological perspective MW, BF, AP
Providing a clinical perspective MW, BF, AP
Providing a policy perspective MW
Writing the review MW, BF, AP
Providing general advice on the review MW
Updates of review
Task Author
Screening search results AP, MW,TG, LA, ZHH
Organising retrieval of papers AP,TG, LA, ZHH
Screening retrieved papers against inclusion criteria and appraising
risk of bias
AP, MW,TG, LA, ZHH
Abstracting data from papers AP, MW, LA, ZHH
Writing to authors of papers for additional information AP, ZHH
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(Continued)
Data management for the updated review and data entry AP, LA, ZHH
Analysis and interpretation of data AP, MW, LA, ZHH
Providing a methodological and clinical perspective AP, MW, LA, ZHH
Providing a policy perspective MW
Writing the update AP, MW,TG, LA, ZHH
Providing general advice on the review AP,MW
D E C L A R A T I O N S O F I N T E R E S T
Martin Wildman works intensively in the area of adherence working to understand how preventative nebulised treatment can decrease
the need for IV antibiotics. He has received support from Respironics in terms of salary support for a research fellow who has worked
on adherence research. He has also received funding from Smiths Medical for work around adherence device developments, funding
from Pari to develop software to measure drug duration, and funding from Philips to use airflow data to try to predict exacerbations.
He has also been paid for consultancy relating to adherence by Vertex Inc (Vertex do not manufacture or market antibiotics).
Amanda Plummer has received an honrarium from Profile Pharmaceuticals and from the Chiesi advisory board related to preventative
nebulised treatment; these do not constitute a conflict of interest for this review which is looking at the duration of intravenous antibiotic
treatment.
Linsey Abbott declares no known potential conflict of interest.
Zhe Hui Hoo declares funding from a CF Trust clinical fellowship (Award Identifier CF007).
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the
Cochrane Cystic Fibrosis and Genetic Disorders Group.
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N O T E S
At the update in 2010 Dr Bryan Fernandes left the review team and Amanda Plummer took on the role of lead author.
At the update in 2015 Tim Gleeson joined the review team for the review update.
At the update in 2019 Linsey Abbott and Dr Zhe Hui Hoo joined the team, replacing Tim Gleeson.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Bacterial Agents [∗administration & dosage]; Bacterial Infections [∗drug therapy]; Cystic Fibrosis [∗complications]; Drug Admin-
istration Schedule; Injections, Intravenous; Lung Diseases [∗drug therapy]
MeSH check words
Humans
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